PA
BLPH

Perceptive Advisors’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Perceptive Advisors’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-930,000
Closed -$7.34M – 114
2023
Q1 		$7.34M Buy
+930,000
New +$3.24M 0.22% 72

Other funds holding BLPH

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors's BLPH Position: Q2 2023 in Review

Perceptive Advisors sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2023, closing a stake of 930,000 shares — an estimated $7.34M sold.

Perceptive Advisors first reported a position in BLPH in Q1 2023 and held it in 1 quarter. The position peaked at $7.34M in Q1 2023. 23 funds tracked by Wall St. Rank hold BLPH as of Q2 2023.

  • Perceptive Advisors reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Perceptive Advisors sold 930,000 Bellerophon Therapeutics, Inc. shares in Q2 2023, an estimated $7.34M.
  • Perceptive Advisors first reported a position in Bellerophon Therapeutics, Inc. in Q1 2023 and held it in 1 quarter.
  • Perceptive Advisors's Bellerophon Therapeutics, Inc. position peaked at $7.34M in Q1 2023.
  • 23 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2023.

Based on Perceptive Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.